Current approaches to therapy design and treatment strategies fall short in addressing a critical challenge of precision medicine: only a small fraction of treated patients respond to precision-targeted drugs. An even more concerning limitation is our present inability to predict drug responses for non-responders—especially in life-threatening conditions such as aggressive cancers, where negative biomarker results may leave insufficient time to pursue alternative treatments. Consequently, accurately predicting therapeutic responses in these high-risk patients or identifying optimal candidates for specific therapies remains a pressing and unresolved clinical need. For years, clinicians have grappled with a fundamental question: Why do some patients experience dramatic—sometimes complete—clinical responses, while most see little to no benefit? The challenge lies in identifying non-responders early and determining what interventions could convert them into responders. Emerging research is now shedding light on why certain cancer patients fail to respond to precision therapies, offering hope for guiding patients and physicians toward more effective treatments. One particularly promising frontier is the use of gene–drug mapping technologies, which could revolutionize care by transforming non-responders into responders. Additionally, understanding the interplay between cancer cells and the immune system may unlock the full potential of precision medicine, bringing us closer to effective therapies for every cancer patient.

1. Bizuayehu HM, Ahmed KY, Kibret GD, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi: 10.1001/jamanetworkopen.2024.43198
2. Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017;123(6):917-927. doi: 10.1002/cncr.30430
3. MacDonald WJ, Purcell C, Pinho-Schwermann M, Stubbs NM, Srinivasan PR, El-Deiry WS. Heterogeneity in Cancer. Cancers. 2025;17(3):441. doi: 10.3390/cancers17030441
4. Ramón Y Cajal S, Sesé M, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med. 2020;98(2):161-177. doi: 10.1007/s00109-020-01874-2
5. Yeh C, Lin ST, Yeh S. Single-Cell Spatial Transcriptomics Reveals Cellular and Molecular Heterogeneity of Non- Small Cell Lung Cancer. Canc Therapy & Oncol Int J. 2024;27(3):556213. doi: 10.19080/CTOIJ.2024.27.556213
6. Jamalinia M, Weiskirchen R. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Ann Transl Med. 2025;13(2):18. doi: 10.21037/atm-25-34
7. Li L, Xie W, Zhan L, et al. Resolving tumor evolution: a phylogenetic approach. J Natl Cancer Cent. 2024;4(2):97- 106. doi: 10.1016/j.jncc.2024.03.001
8. Kay EJ, Zanivan S. The tumor microenvironment is an ecosystem sustained by metabolic interactions. Cell Rep. 2025;44(3):115432. doi: 10.1016/j.celrep.2025.115432
9. Król K, Mazur A, Stachyra-Strawa P, Grzybowska- Szatkowska L. Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review. Int J Mol Sci. 2023;24(6):5858. doi: 10.3390/ijms24065858
10. Lei ZN, Tian Q, Teng QX, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3):e265. doi: 10.1002/mco2.265
11. Stubbs NM, Roady TJ, Schwermann MP, et al. Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resist. 2025;8:27. doi: 10.20517/cdr.2024.189
12. Boshuizen J, Peeper DS. Rational Cancer Treatment Combinations: An Urgent Clinical Need. Mol Cell. 2020;78(6):1002-1018. doi: 10.1016/j.molcel.2020.05.031
13. Huang Q, Li Y, Huang Y, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. Sig Transduct Target Ther. 2025;10:186. doi: 10.1038/s41392-025-02243-6
14. Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med. 2023;11(10):358. doi: 10.21037/atm-22-4444
15. Ko YH, Lee MA, Hong YS, et al. Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients. Korean J Intern Med. 2007;22(3):178-185. doi: 10.3904/kjim.2007.22.3.178
16. Mastromarino MG, Guerrini E, Caciagli LM, et al. Salvage Surgery: A Concrete Opportunity in Unresectable Non- Small Cell Lung Cancer Following Definitive Chemo- Immunotherapy. Cancers. 2025;17(18):2967. doi: 10.3390/cancers17182967
17. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(22):2109-2121. doi: 10.1056/NEJMoa1616288
18. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371-2381. doi: 10.1056/NEJMoa2103695
19. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/ LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099
20. Arbour KC, Mezquita L, Long N, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006
21. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819-829. doi: 10.1056/NEJMoa1604958
22. Pathak R, Amini A, Hill A, Massarelli E, Salgia R. Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. Cancers. 2021;13(14):3407. doi: 10.3390/cancers13143407
23. White E, Lattime EC, Guo JY. Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity. Trends Cancer. 2021;7(8):778-789. doi: 10.1016/j.trecan.2021.05.003
24. Ercan D, Choi HG, Yun CH, et al. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res. 2015;21(17):3913-3923. doi: 10.1158/1078-0432.CCR-14-2789
25. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011;17(17):5530-5537. doi: 10.1158/1078-0432.CCR-10-2571
26. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80. doi: 10.1016/j.cell.2010.02.027
27. Herbst R, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454. doi: 10.1038/nature25183
28. Choi YJ, Kim SY, So KS, et al. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS ONE. 2015;10(3):e0119832. doi: 10.1371/journal.pone.0119832
29. Rivera-Concepcion J, Uprety D, Adjei AA. Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer. Cancer Res Treat. 2022;54(2):315-329. doi: 10.4143/crt.2022.078
30. Leighl NB, Page RD, Raymond VM, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019;25(15):4691-4700. doi: 10.1158/1078-0432.CCR-19-0624
31. Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693-1704. doi: 10.1038/ng.3990
32. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948. doi: 10.1056/NEJMoa2306434
33. Wu JJ, Zheng ZR, Lo TH, Chu CH, Chen KC, Chang GC. Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma. JTO Clin Res Rep. 2025;6(6):100832. doi: 10.1016/j.jtocrr.2025.100832
34. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. doi: 10.1038/nature22364
35. Schiffmann I, Greve G, Jung M, Lübbert M. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics. 2016;11(12):858-870. doi: 10.1080/15592294.2016.1237345
36. Shi X, Deng W, Pan Y, Chen Y, Wang Y, Wu J. Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy. Front Immunol. 2025;16:1691980. doi: 10.3389/fimmu.2025.1691980
37. Hu W, Zhao Z, Du J, et al. Interferon signaling and ferroptosis in tumor immunology and therapy. NPJ Precis Oncol. 2024;8:177. doi: 10.1038/s41698-024-00668-w
38. Khan T, Nagarajan M, Kang I, Wu C, Wangpaichitr M. Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy. J Pers Med. 2025;15(2):50. doi: 10.3390/jpm15020050
39. Desharnais L, Sorin M, Rezanejad M, et al. Spatially mapping the tumour immune microenvironments of non-small cell lung cancer. Nat Commun. 2025;16(1):1345. doi: 10.1038/s41467-025-56546-x
40. Herbst RS, Gandara DR, Hirsch FR, et al. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514-1524. doi: 10.1158/1078-0432.CCR-13-3473
41. Verduin M, Hoeben A, De Ruysscher D, Vooijs M. Patient- Derived Cancer Organoids as Predictors of Treatment Response. Front Oncol. 2021;11:641980. doi: 10.3389/fonc.2021.641980
42. Hua P, Olofson A, Farhadi F, et al. Predicting targeted therapy resistance in non-small cell lung cancer using multimodal machine learning. J Thorac Dis. 2025;17(10):8700-8714. doi: 10.21037/jtd-2025-1012
43. Yeh C, Lin ST, Lai HC. A Transformative Technology Linking Patient’s mRNA Expression Profile to Anticancer Drug Efficacy. Onco. 2024;4(3):143-162. doi: 10.3390/onco4030012
44. Yeh C. Circulating cell-free transcriptomics in cancer. J Lung Pulm Respir Res. 2023;10:23-25. doi: 10.15406/jlprr.2023.10.00297
45. Yeh C, Lin ST, Baranski A, Yeh S. Revolutionizing drug response prediction: An unmet requirement for patients unresponsive to precision medicine. Global Transl Med. 2025;4(2):3-11. doi: 10.36922/gtm.5091
46. Allison Stewart C, Tong P, Cardnell RJ, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017;8(17):28575-28587. doi: 10.18632/oncotarget.15338
47. Lin ST, Lai HC, Schill P, Yeh C. The one-of-a-kind PGA technology harnesses patient’s gene signature to predict drug efficacy: A reality check with the real-world treatment trend. Tumor Discov. doi: 10.36922/TD025520129
48. Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. Drugs Real World Outcomes. 2022;9(3):333-345. doi: 10.1007/s40801-022-00302-w
49. Kim YJ, Oremus M, Chen HH, McFarlane T, Shah D, Horton S. Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncol. 2020;16(27):2045-2058. doi: 10.2217/fon-2020-0248
50. Rittberg R, Leung B, Shokoohi A, et al. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Curr Oncol. 2023;30(6):5299-5308. doi: 10.3390/curroncol30060402
51. Janžič U, Turnšek N, Dediu M, et al. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT). Curr Oncol. 2022;29(8):5833-5845. doi: 10.3390/curroncol29080460
52. Leal TA, Dasgupta A, Latremouille-Viau D, et al. Real- World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan. JCO Glob Oncol. 2024;10:e2300483. doi: 10.1200/GO.23.00483
53. Lazzari C, Bulotta A, Ducceschi M, et al. Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. Front Med. 2017;4:4. doi: 10.3389/fmed.2017.00004
54. Dogiparthi LK, Bukke SPN, Thalluri C, et al. The role of genomics and proteomics in drug discovery and its application in pharmacy. Discov Appl Sci. 2025;7:552. doi: 10.1007/s42452-025-07155-2
55. Saraswathi TS, Mothilal M, Bukke SPN, Thalluri C, Chettupalli AK. Recent advances in potential drug nanocarriers for CNS disorders: a review. Biomed Eng Online. 2025;24(1):137. doi: 10.1186/s12938-025-01474-6
56. Onohuean H, Naik Bukke SP, Thalluri C, Abass KS, Choonara YE. Exosome engineering for targeted therapy of brain-infecting pathogens: molecular tools, delivery platforms, and translational advances. Front Med Technol. 2025;7:1655471. doi: 10.3389/fmedt.2025.1655471